Respectful Parenting: Child Clinical Psychology in the Protection of Children's Mental Health

Introduction: The arrival of the pandemic in our country has meant that families face a negative emotional burden and an overload of roles associated with the care and satisfaction of children and adolescents' needs;the Respectful Parenting project arises in a context where Child Clinical Psychology needed to support much more children's mental health. Objective: Promoting or restoring the psychological well-being of children and adolescents through the support and preparation of their primary caregivers. Methods: The target population is the thousands of parents and caregivers who make up the project services. The methodology is qualitative action research. Results: The main children's problems and the support requirements of their caregivers are identified. The project is structured in three services that complement each other. The systematic assessment in the sessions and the one directed to a sample of project beneficiaries show very favorable results. Conclusions: The project assesses the needs of the target public. It is designed, implemented and achieves positive results in its evaluation. It manages to promote or recover the psychological well-being of infants through the support and preparation of their main caregivers © Este material es publicado según los términos de la Licencia Creative Commons Atribución–NoComercial 4.0. Se permite el uso, distribución y reproducción no comerciales y sin restricciones en cualquier medio, siempre que sea debidamente citada la fuente primaria de publicación

Identification of highly immunogenic epitopes in the SARS-CoV-2 Spike protein to produce monoclonal antibodies

Background: In outpatients, monoclonal antibodies to Spike protein reduce viral load and improve outcomes, with a greater effect in serum antibody-negative at baseline. The aim of this study was to find epitope candidates to produce neutralizing monoclonal antibodies (mAb) for COVID-19 treatment. Method(s): IgG COVID-19 patients (N=500) against SARS-CoV-2 was confirmed. Epitope mapping was performed by Luminex technology. A computational pipeline based in predictive models was designed to predict S protein epitopes most likely to be recognized by mAb from COVID-19 convalescent patients. Result(s): Validation Screening: 29 epitopes of the SARS-CoV-2 S protein were predicted by our pipeline and included in the Luminex panel. 40 serum samples from convalescent COVID-19 patients and 126 pre-pandemia negative controls were included in the validation screening. Epitope mapping: 500 serum samples were tested against the 8 epitopes selected in the validation screening. The two epitopes with the highest IgG of participants above the seropositivity cut-offs were selected. The two most immunogenic epitopes were screened in phage library containing 109 clones of antibodies anti-SARS-CoV-2 to produce mAbs by phage display technology. Conclusion(s): The two epitopes with the highest IgG reactivity validated against serum samples from 500 COVID-19 convalescent patients and phage library are good candidates for the production of new neutralizing mAbs against SARS-CoV-2 S protein.

A Nobel Score to Predict Pediatric Covid-19 Severity in Low and Middle Income Countries

BACKGROUND AND AIM: COVID-19 affects children less seriously than adults;however, severe cases and deaths are documented. This study objective is to determine sociodemographic, clinical and laboratory indicators associated with severe pediatric COVID-19 and mortality at hospital entrance. METHOD(S): A multicenter, retrospective, cross-sectional study was performed in 13 tertiary hospitals in Bolivia. Clinical records were collected retrospectively from patients less than 18 years of age and positive for SARS-CoV-2 infection. All variables were measured at hospital entrance;outcomes of interest were ICU admission and death. A score for disease severity was developed using a logistic regression model. RESULT(S): 209 patients were included in the analysis. By the end of the study, 43 (20.6%) of children were admitted to the Intensive care unit (ICU), and 17 (8.1%) died. Five indicators were independently predictive of COVID-19 severity: age below 10 years OR: 3.3 (CI95%: 1.1 - 10.4), days with symptoms to medical care OR: 2.8 (CI95%: 1.2 - 6.5), breathing difficulty OR: 3.4 (CI95%: 1.4 - 8.2), vomiting OR: 3.3 (CI95%: 1.4 - 7.4), cutaneous lesions OR: 5.6 (CI95%: 1.9 - 16.6). Presence of three or more of these risk factors at hospital entrance predicted severe disease in COVID-19 positive children. Age, presence of underlying illness, male sex, breathing difficulty, and dehydration were predictive of death in COVID-19 children. CONCLUSION(S): Our study identifies several predictors of severe pediatric COVID-19 and death. Incorporating these predictors, we developed a tool that clinicians can use to identify children at high risk of severe COVID-19 in limited resource settings.

Environmental Variables and their Relation with the SARS-COV-2 Transmission: A Data Mining Approach

In the present paper are analyzed the correlations between the meteorological variables such as maximum temperature, minimum temperature, relative humidity, precipitation with the number of infections by SARS-CoV-2. The data set for the meteorological variables was obtained from web site of the National Service of Meteorology and Hydrology of Peru (SENAMHI), while the number of infections by SARS-CoV-2 was obtained from the denominated data positive by COVID 19 reported in web site by the Ministry of Health from Peru. After the preprocessing and the fusion of the data sets, it was obtained a data subset with 365 registers and 6 columns. To detect the correlations between the meteorological variables and the number of infections by SARS-CoV-2, the Spearman's rank correlation coefficient was computed. The results show significant correlations between the variables minimum temperature and number of infections by SARS-CoV-2 for a rho=-0.45, pvalor=0.00<0.05;relative humidity and number of infections by SARS-CoV-2 for a rho=-0.24, pvalor=0.00<0.05;precipitation and number of infections by SARS-CoV-2 for a rho=-0.24, p-valor=0.00<0.05. According to the results obtained, we concluded that minimum temperatures facilitate the SARS-CoV-2 transmissibility.

Impact Assessment for Data Network's Rehabilitation. Case of Ecuador

Access to the Internet is necessary to ensure equity for the right to education. However, about 75% of school-age children in rural areas of the world do not have access to the Internet at home. In the Ecuadorian context, only 5.1% of the rural population uses the Internet in public/state schools. Therefore, actions are necessary to reduce the digital gap to improve the quality of education in rural communities in Ecuador. An initiative of IEEE Ecuador, with the support of IEEE SIGHT and the Municipality of Nabón, allowed the rehabilitation of a data network in 40 schools in the Nabón community in 2020. This paper examines the impact of the project, through of the collection of quantitative and qualitative data through stakeholder surveys, to evaluate the impact of data network rehabilitation in the community during the first year of operation. The results show that the Internet in schools has improved the quality of education for students, has allowed children and young people to have access to online education during the COVID-19 pandemic, and has decreased the dropout rate in the benefited schools. The Internet service in schools has also allowed families to save money and entertain themselves. The paper also reports on the evaluation of the social impact of the project, through a Social Return On Investment (SROI) analysis. © 2021 IEEE.

1061P Safety of cemiplimab for advanced cutaneous squamous cell carcinoma: The Spanish named patient programme

Background: Cemiplimab is a programmed cell death receptor-1 inhibitor with antitumour activity for cutaneous squamous cell carcinoma (CSCC) and acceptable safety proved in its pivotal trial. We provide the first data on cemiplimab safety in daily practice from the named patient programme (NPP) for advanced CSCC in Spain. Methods: This cemiplimab NPP was performed from March 2019 to March 2020. It included patients aged ≥18 years with advanced CSCC and ineligible for surgery, radiation therapy or clinical trials. The cemiplimab safety was assessed according to treatment-emergent adverse events (TEAEs) reported until March 2021. Results: 140 patients were included (median age [interquartile range, IQR] 77.0 [65.0-84.0] years;age ≥80 38%;men 71.7%;≥1 comorbidity 83%;ECOG 0-1 86.3%;locally advanced CSCC 60.7%;cemiplimab as first-line therapy 67.7%). Cemiplimab was received for a median (IQR) of 8.0 (3.0-14.0) cycles. Fifty-eight (41.4%) patients showed ≥1 of the 163 TEAEs reported, which most frequently included diarrhoea n=7, asthenia n=6, constipation n=4 and abdominal pain n=4. Fourteen (8.6%) were immune-mediated, mainly bronchitis n=2, pneumonitis n=2 and hepatitis n=2. Seventy-eight (47.9%) TEAEs were grade ≥3, most frequently pneumonia n=3, COVID-19 n=3, general physical health deterioration n=2, pyrexia n=2, renal transplant failure n=2, sepsis n=2, acute kidney injury n=2 and respiratory failure n=2. Twenty-one (12.9%) were treatment-related (TREAEs): 11 (6.7%) were grade 1-2 (diarrhoea n=3 and asthenia, hepatotoxicity, malnutrition, odynophagia, polymyalgia rheumatica, pneumonitis, pruritus, and skin toxicity), 9 (5.5%) grade 3 (acute kidney injury, adrenal insufficiency, abdominal pain, blood creatinine increased, dysphagia, haematuria, immune-mediated enterocolitis, panniculitis, surgical wound infection) and 1 (0.6%) unknown grade. Cemiplimab was withdrawn due to TREAEs in only 5 (3.6%) patients. The TEAE outcome was fatal in 29 (17.8%);none related to cemiplimab. Conclusions: This NPP supports the real-life safety of cemiplimab for CSCC, showing an acceptable safety profile consistent with previous reports. Editorial acknowledgement: Editorial assistance was provided by Esther Álvarez-García at Dynamic Science S.L., funded by Sanofi. Legal entity responsible for the study: Sanofi. Funding: Sanofi. Disclosure: E. Muñoz Couselo: Financial Interests, Personal, Advisory Board: Amgen;Financial Interests, Personal, Advisory Board: Bristol-Myers Squibb;Financial Interests, Personal, Advisory Board: Merck Sharp & Dohme;Financial Interests, Personal, Advisory Board: Novartis;Financial Interests, Personal, Advisory Board: Pierre Fabre;Financial Interests, Personal, Advisory Board: Roche;Financial Interests, Personal, Advisory Board: Sanofi;Financial Interests, Personal, Other, Honoraria: Amgen;Financial Interests, Personal, Other, Honoraria: Bristol-Myers Squibb;Financial Interests, Personal, Other, Honoraria: Merck Sharp & Dohme;Financial Interests, Personal, Other, Honoraria: Novartis;Financial Interests, Personal, Other, Honoraria: Pierre Fabre;Financial Interests, Personal, Other, Honoraria: Roche;Financial Interests, Personal, Principal Investigator: Amgen;Financial Interests, Personal, Principal Investigator: Bristol-Myers Squibb;Financial Interests, Personal, Principal Investigator: GlaxoSmithKline;Financial Interests, Personal, Principal Investigator: Merck Sharp & Dohme;Financial Interests, Personal, Principal Investigator: Novartis;Financial Interests, Personal, Principal Investigator: Pierre Fabre;Financial Interests, Personal, Principal Investigator: Roche;Financial Interests, Personal, Principal Investigator: Sanofi. A. Soria: Financial Interests, Personal, Invited Speaker: Novartis;Financial Interests, Personal, Invited Speaker: Sanofi Aventis;Financial Interests, Personal, Invited Speaker: Roche Pharma;Financial Interests, Personal, Invited Speaker: Merck Serono;Financial Interests, Personal, Invited Speaker: Merck Sharp & Dohme;Financial Interests, Perso al, Invited Speaker: Bristol-Myers Squibb;Financial Interests, Personal, Invited Speaker: Pierre Fabre;Financial Interests, Personal, Advisory Board: Novartis;Financial Interests, Personal, Advisory Board: Sanofi Aventis;Financial Interests, Personal, Advisory Board: Roche Pharma;Financial Interests, Personal, Advisory Board: Merck Serono;Financial Interests, Personal, Advisory Board: Merck Sharp & Dohme;Financial Interests, Personal, Advisory Board: Bristol-Myers Squibb;Financial Interests, Personal, Advisory Board: Pierre Fabre;Financial Interests, Personal, Principal Investigator: Novartis;Financial Interests, Personal, Principal Investigator: Sanofi Aventis;Financial Interests, Personal, Principal Investigator: Roche Pharma;Financial Interests, Personal, Principal Investigator: Merck Serono;Financial Interests, Personal, Principal Investigator: Merck Sharp & Dohme;Financial Interests, Personal, Principal Investigator: Bristol-Myers Squibb;Financial Interests, Personal, Principal Investigator: Pierre Fabre. O. Sanmartin: Financial Interests, Personal, Invited Speaker: Sanofi Genzyme;Financial Interests, Personal, Advisory Board: Sanofi Genzyme;Financial Interests, Personal, Officer: Sanofi Genzyme;Financial Interests, Personal, Principal Investigator: Sanofi Genzyme;Financial Interests, Personal, Invited Speaker: Roche Pharma;Financial Interests, Personal, Advisory Board: Roche Pharma;Financial Interests, Personal, Officer: Roche Pharma;Financial Interests, Personal, Principal Investigator: Roche Pharma. J. Cañueto: Financial Interests, Personal, Invited Speaker: Hoffman-La Roche;Financial Interests, Personal, Invited Speaker: Sanofi-Genzyme;Financial Interests, Personal, Invited Speaker: AbbVie;Financial Interests, Personal, Invited Speaker: LeoPharma;Financial Interests, Personal, Other, Consultancy: Sanofi-Genzyme;Financial Interests, Personal, Other, Consultancy: InflaRx;Financial Interests, Personal, Other, Consultancy: Almirall. S. Beá Ardébol: Financial Interests, Personal, Invited Speaker: Meda;Financial Interests, Personal, Advisory Board: Sanofi;Financial Interests, Personal, Advisory Board: SunPharma;Financial Interests, Personal, Other, Trial subinvestigator: Sanofi Aventis;Financial Interests, Personal, Other, Trial subinvestigator: SunPharma;Financial Interests, Personal, Other, Trial subinvestigator: PellePharma. R. Fernández-de-Misa Cabrera: Financial Interests, Personal, Advisory Board: Sanofi. A.J. Cunquero-Tomás: Financial Interests, Personal, Invited Speaker: BMS;Financial Interests, Personal, Invited Speaker: Pierre-Fabre;Financial Interests, Personal, Writing Engagements: Sanofi;Financial Interests, Personal, Other, 2021 EADO/WMC Congress inscription fee: Sanofi. L. Fernández Franco: Non-Financial Interests, Personal, Invited Speaker: Merck;Non-Financial Interests, Personal, Invited Speaker: Sanofi;Non-Financial Interests, Personal, Invited Speaker: Servier. I. Romero: Financial Interests, Personal, Invited Speaker: Pharmamar;Financial Interests, Personal, Invited Speaker: Roche;Financial Interests, Personal, Invited Speaker: GSK;Financial Interests, Personal, Invited Speaker: Clovis;Financial Interests, Personal, Invited Speaker: AstraZeneca;Financial Interests, Personal, Advisory Board: Pharmamar;Financial Interests, Personal, Advisory Board: Roche;Financial Interests, Personal, Advisory Board: GSK;Financial Interests, Personal, Advisory Board: Clovis;Financial Interests, Personal, Advisory Board: AstraZeneca. J. Medina Martínez: Non-Financial Interests, Personal, Invited Speaker: Roche;Non-Financial Interests, Personal, Speaker’s Bureau: Roche;Non-Financial Interests, Personal, Advisory Board: Roche;Non-Financial Interests, Personal, Invited Speaker: Novartis;Non-Financial Interests, Personal, Speaker’s Bureau: Novartis;Non-Financial Interests, Personal, Advisory Board: Novartis;Non-Financial Interests, Personal, Invited Speaker: BMS;Non-Financial Interests, Personal, Speaker’s Bureau: BMS;Non-Financial Interests, Personal, Ad isory Board: BMS;Non-Financial Interests, Personal, Invited Speaker: MSD;Non-Financial Interests, Personal, Speaker’s Bureau: MSD;Non-Financial Interests, Personal, Invited Speaker: Pierre Fabre;Non-Financial Interests, Personal, Speaker’s Bureau: Pierre Fabre;Non-Financial Interests, Personal, Advisory Board: Pierre Fabre;Non-Financial Interests, Personal, Invited Speaker: Merk;Non-Financial Interests, Personal, Speaker’s Bureau: Merk;Non-Financial Interests, Personal, Invited Speaker: Sanofi;Non-Financial Interests, Personal, Speaker’s Bureau: Sanofi;Non-Financial Interests, Personal, Advisory Board: Sanofi;Non-Financial Interests, Personal, Invited Speaker: Servier. All other authors have declared no conflicts of interest.

Treatment proposals for SARS-CoV-2 infection: Analyzing the evidence

The pandemic caused by infection with the new SARS-CoV-2 coronavirus has brought unprecedented mortality. Its high contagiousness and lethality, especially in vulnerable patients, has led to an urgent search for drugs that have a potential benefit in controlling this pandemic. Research to develop a new drug involves long periods of experimentation. For this reason, scientists have focused on testing the use of pre-existing drugs, even when their initial purpose is not an antiviral effect. In this review, we will analyze the evidence of the different proposed treatment options, with emphasis on their mechanism of action and the benefits found in observational studies. © 2020 Comunicaciones Cientificas Mexicanas S.A. de C.V.. All rights reserved.